StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > The one Quote the stuck out to me

<< Previous

Bullboard Posts

Next >>

Comment by InvrsContrarianon Jan 07, 2021 11:41am

190 Views

Post# 32242314

RE:RE:The one Quote the stuck out to me

Rhetorical question. P/E ratio of biotech with good revenue runs 15-40 times. Analysts take an average of 30 times. We are in for the ride of a lifetime. I'm staying strong although I maybe a short term investor. Less than a year, but dude advertised come for covid and stay for cancer. I'm glad I found szls. />

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market